Invivyd, Inc. Form 8-K Summary
Business Context and Reporting Period
Invivyd, Inc. (IVVD), a biopharmaceutical company, filed this Current Report on Form 8-K on November 17, 2025. The filing details the entry into a material definitive agreement for an underwritten public offering of common stock and pre-funded warrants. The offering closed on November 19, 2025.
Key Financial Metrics
- Offering Size: 44,000,000 shares of Common Stock and pre-funded warrants for 6,000,000 shares.
- Offering Price: $2.50 per share for Common Stock; $2.4999 per Pre-Funded Warrant.
- Net Proceeds: Approximately $117.2 million after underwriting discounts, commissions, and estimated offering expenses.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional 7,500,000 shares at the public offering price.
- Revenue, Profit, and Cash Flow: This filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity metrics for the reporting period.
Material Changes
The primary material change is the significant increase in capital raised through the public offering. The filing does not provide comparative financial data against prior periods to quantify changes in operating metrics.
Guidance, Outlook, and Use of Proceeds
Management intends to use the net proceeds for the following purposes:
- Commercial preparedness for the potential launch of VYD2311.
- Continued research and development for pipeline programs, including respiratory syncytial virus (RSV) and measles.
- Advancement of the Spike Protein Elimination and Recovery (SPEAR) Study Group efforts regarding Long COVID and COVID-19 Post-Vaccination Syndrome.
- Working capital and general corporate purposes.
Risks and Contingencies: The filing includes a cautionary note regarding forward-looking statements, citing risks related to general market conditions and factors detailed in the Company's Form 10-K and Form 10-Q filings. The Pre-Funded Warrants include ownership limitations (4.99% or 9.99% initial cap) and are exercisable in cash or cashless.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $117.2 million net proceeds.
- Review the prospectus supplement dated November 17, 2025, for detailed risk factors and use of proceeds.
- Monitor the exercise of the 30-day over-allotment option for an additional 7,500,000 shares.
- Check subsequent filings for updates on the commercial launch timeline of VYD2311.
- Review the latest Form 10-Q (ended September 30, 2025) for current cash position and burn rate prior to this capital raise.